Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek, a monoclonal antibody, is approved for the treatment of Crohn's disease, olcerative colitis, plaque psoriasis, and ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) ...

The biosimilar is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis ...

Biocon Biologics Ltd (BBL) has received US Food and Drug Administration (FDA) approval for Yesintek, a biosimilar for Johnson ...

Collaboration with Janssen aims to fast-track the launch and enhance accessibility to YESINTEK for patients in need.

US FDA approves Biocon Biologics’ Yesintek, Bmab 1200 biosimilar to J&J's Stelara: Our Bureau, Bengaluru Monday, December 2, 2024, 16:15 Hrs [IST] Biocon Biologics subsidiary of ...

The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...

Biocon Biologics the biosimilars company and subsidiary of Indian drugmaker Biocon, has announced that the US Food and Drug ...